Autoimmune CAR-T Development Trends and Insights

This document is a research report outlining the recent developments in CAR-T therapies for autoimmune diseases. It discusses the evolution of CAR-T from a conceptual stage to a strategic focus within the field. The report highlights early clinical indications that suggest the potential for significant immune reset in patients with refractory diseases. It documents the acceleration of clinical trials and investment in CAR-T applications beyond oncology, noting that the modality is emerging as a third significant approach alongside monoclonal antibodies and small molecule inhibitors. The findings illustrate the rapid rise in CAR-T trial activity post-2022, especially in indications such as lupus, multiple sclerosis, and scleroderma. The report also analyzes target selection strategies within CAR-T development, emphasizing the importance of targeting B-cell compartments to achieve durable treatment outcomes. Overall, the report presents a detailed examination of the shifts in autoimmune R&D, outlining both the challenges and promising developments in CAR-T therapies.